(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: A potent, selective, orally active dipeptidyl peptidase IV inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 7, 2009, Pages 1991-1995

  Ammirati, Mark J ^a   Andrews, Kim M ^a   Boyer, David D ^a   Brodeur, Anne M ^a   Danley, Dennis E ^a   Doran, Shawn D ^a   Hulin, Bernard ^a   Liu, Shenping ^a   McPherson, R Kirk ^a   Orena, Stephen J ^a   Parker, Janice C ^a   Polivkova, Jana ^a   Qiu, Xiayang ^a   Soglia, Carolyn B ^a   Treadway, Judith L ^a   VanVolkenburg, Maria A ^a   Wilder, Donald C ^a   Piotrowski, David W ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diabetes; Dipeptidyl peptidase IV; DPP 4

Indexed keywords

(3,3 DIFLUOROPYRROLIDIN 1 YL) [4 (4 PYRIMIDIN 2 YL PIPERAZIN 1 YL)PYRROLIDIN 2 YL]METHANONE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PF 00734200; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; MONKEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; HUMANS; HYPOGLYCEMIC AGENTS; PYRIMIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61849146383     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.041     Document Type: Article

References (27)

1. For comprehensive reviews on DPP-4 inhibitors, see:. Idris I., and Donnelly R. Diabetes Obes. Metab. 9 (2007) 153
2. von Geldern T.W., and Trevillyan J.M. Drug Dev. Res. 67 (2006) 627
3. Weber A.E. J. Med. Chem. 47 (2004) 4135
4. Peters J.-U. Curr. Top. Med. Chem. 7 (2007) 579
5. Hopkins A.L., Groom C.R., and Alex A. Drug Discov. Today 9 (2004) 430
6. Pospisilik J.A., Stafford S.G., Demuth H.-U., Brownsey R., Parkhouse W., Finegood D.T., McIntosh C.H.S., and Pederson R.A. Diabetes 51 (2002) 943
7. For a discussion of toxicities associated with thiazolidides like P32/98, see:. Thornberry N.A., and Weber A.E. Curr. Top. Med. Chem. 7 (2007) 557
8. Hulin B., Cabral S., Lopaze M.G., Van Volkenberg M.A., Andrews K.M., and Parker J.C. Bioorg. Med. Chem. Lett. 15 (2005) 4770
9. Edmondson S.D., Mastracchio A., Mathvink R.J., He J., Harper B., Park Y.-J., Beconi M., Di Salvo J., Eiermann G.J., He H., Leiting B., Leone J.F., Levorse D.A., Lyons K., Patel R.A., Patel S.B., Petrov A., Scapin G., Shang J., Roy R.S., Smith A., Wu J.K., Xu S., Zhu B., Thornberry N.A., and Weber A.E. J. Med. Chem. 49 (2006) 3614
10. Yoshida T., Sakashita H., Akahoshi F., and Hayashi Y. Bioorg. Med. Chem. Lett. 17 (2007) 2618 and refereneces cited therein
11. 6O: C, 55.73; H, 6.60; N, 22.94. Found: C, 55.78; H, 6.54; N, 22.68.
12. DPP-2 substrate 200 μM Lys-Ala-β-naphthylamide. See:. McDonald J.K., Leibach F.H., Grindeland R.E., and Ellis S. J. Biol. Chem. 243 (1968) 4143-4150
13. DPP-3 substrate 125 μM Arg-Arg-AMC. See:. Abramic M., Zubanovic M., and Vitale L. Biol. Chem. 369 (1988) 29-38
14. DPP-8 substrate 200 μM Ala-Pro-AMC. See:. Abbot C.A., Yu D.M., Woollatt E., Sutherland G.R., McCaughan G.W., and Gorrell M.D. Eur. J. Biochem. 267 (2000) 6140-6150
15. DPP-9 substrate 200 μM Ala-Pro-AMC. See:. Olsen C., and Wagtmann N. Gene 299 (2002) 185-193
16. FAP substrate 200 μM Ala-Pro-AMC. See:. Scanlan M.J., Raj B.K.M., Calvo B., Garin-Chesa P., Sanz-Moncasi M.P., Healey J.H., Old L.J., and Rettig W.J. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 5657-5661
17. APP substrate 500 μM Arg-Pro-Pro. See:. Rusu I., and Yaron A. Eur. J. Biochem. 210 (1992) 93-100
18. POP substrate 200 μM Z-Gly-Pro-AMC. See:. Yoshimoto T., Orlowski R.C., and Walter R. Biochemistry 16 (1977) 2942
19. The dipeptidyl peptidase enzyme inhibition assays and rat pharmacokinetic assays are described in:. Wright S.W., Ammirati M.J., Andrews K.M., Brodeur A.M., Danley D.E., Doran S.D., Lillquist J.S., McClure L.D., McPherson R.K., Orena S.J., Parker J.C., Polivkova J., Qiu X., Soeller W.C., Soglia C.B., Treadway J.L., VanVolkenberg M.A., Wang H., Wilder D.C., and Olson T.V. J. Med. Chem. 49 (2006) 3068
20. The pharmacodynamic assay is described in:. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M.E., Patel R.A., Petrov A., Scapin G., Patel S.B., Sinha Roy R., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A., and Weber A.E. J. Med. Chem. 48 (2005) 141
21. Affinity-Assay for the Human ERG Potassium Channel; Greengrass, P. M.; Stewart, M.; Wood, C. M. PCT Patent Application WO 03/021271.
22. Singleton D.H., Boyd H., Steidl-Nichols J.V., Deacon M., de Groot M.J., Price D., Nettleton D.O., Wallace N.K., Troutman M.D., Williams C., and Boyd J.G. J. Med. Chem. 50 (2007) 2931
23. Hamill O.P., Marty A., Neher E., Sakmann B., and Sigworth F.J. Eur. J. Physiol. 391 (1981) 85-100
24. Diaz G.J., Daniell K., Leitza S.T., Martin R.L., Su Z., McDermott J.S., Cox B.F., and Gintant G.A. J. Pharmacol. Toxicol. Methods 50 (2004) 187
25. The structure has been deposited in the Protein Data Bank with the deposition code 3F8S.
26. In vitro clearance values for compound 5: Human liver microsome intrinsic clearance (HLM CLint) < 7.0 mg/mL/kg, n = 4. Human hepatocyte intrinsic clearance (HH Clint) < 7.1 mg/mL/kg, n = 2.
27. Dai H., Gustavson S.M., Preston G.M., Eskra J.D., Calle R., and Hirshberg B. Diabetes Obes. Metab. 10 (2008) 506